Breakthrough in Stomach Cancer Prevention

Breakthrough in stomach cancer prevention

In a major breakthrough for cancer prevention scientists in Chile have developed a new probiotic designed to combat stomach cancer a disease often linked to Helicobacter pylori infection. The innovation is the result of 17 years of research led by Dr. Apolinaria García Cancino at the University of Concepcion. The newly developed probiotic specifically targets H. pylori a bacterium widely recognized as a leading cause of gastric cancer. Clinical …

Enhertu Shows 30 Percent Improvement in Survival for Advanced Gastric Cancer Patients in Clinical Trial

AstraZeneca and Daiichi Sankyo’s cancer drug Enhertu de […]

Enhertu Improves Survival End Points Vs Cyramza/Paclitaxel in HER2+ GC/GEJ

Second-line Enhertu improved key survival end points versus Cyramza plus paclitaxel for HER2+ gastric cancer or gastroesophageal junction adenocarcinoma.

ENHERTU Phase 3 Trial Breakthrough: New Drug Cuts Death Risk by 30% in Advanced Gastric Cancer Patients

Latest Phase 3 data reveals ENHERTU extends survival to 14.7 months in HER2+ gastric cancer, outperforming standard therapy. See full efficacy results.